Evidence map›Paper›PMID 33671367›Full record

ArticleCells2021

Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.

Francesco De Logu, Francesca Galli, Romina Nassini, Filippo Ugolini, Sara Simi, Mara Cossa, Clelia Miracco, Andrea Gianatti, Vincenzo De Giorgi, Eliana Rulli and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Francesco De LoguSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50100 Florence, Italy.ORCID 0000-0001-8360-6929
Francesca GalliMethodology for Clinical Research Laboratory, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Romina NassiniSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50100 Florence, Italy.ORCID 0000-0002-9223-8395
Filippo UgoliniSection of Pathological Anatomy, Department of Health Sciences, University of Florence, 50100 Florence, Italy.ORCID 0000-0003-3603-2111
Sara SimiSection of Pathological Anatomy, Department of Health Sciences, University of Florence, 50100 Florence, Italy.
Mara CossaDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Clelia MiraccoUnit of Pathological Anatomy, Department of Medicine, Surgery, and Neurosciences, University of Siena, 53100 Siena, Italy.
Andrea GianattiPathology Unit, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy.
Vincenzo De GiorgiDermatology Unit, University of Florence, 50100 Florence, Italy.ORCID 0000-0001-6531-7998
Eliana RulliMethodology for Clinical Research Laboratory, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Antonio CossuSection of Pathology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Daniela MassiSection of Pathological Anatomy, Department of Health Sciences, University of Florence, 50100 Florence, Italy.
Mario MandalàDivision of Pathological Anatomy, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy.
University of Florence · ITMario Negri Institute for Pharmacological Research · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITOspedale Papa Giovanni XXIII · ITUniversity of Perugia · ITUniversity of Sassari · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundthe prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. MATERIALS AND

methodsdigital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM ≥ 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort.

resultsin the training cohort, 100 Stage II-III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4

conclusionour findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II-III melanoma patients.

Indexed as

AdultBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedSkin NeoplasmsTumor MicroenvironmentBiomarkers, Tumordigital pathologymelanomatumor infiltrating lymphocytes

Identifiers

PMID33671367
PMCPMC7922113
OpenAlexW3129695199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.